http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 27 May 2026 17:26:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Estrella+Immunopharma%2C++++For%3A+Jun+29/26559212.html si-local-file:///var/storage/secattach/20260527/26559212.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Estrella+Immunopharma%2C++++For%3A+Jun+29/26559212.html Wed, 27 May 2026 17:26:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Estrella+Immunopharma%2C++++For%3A+Jun+29/26559212.html si-local-file:///var/storage/secattach/20260527/26559212.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Estrella+Immunopharma%2C++++For%3A+Jun+29/26559212.html Wed, 27 May 2026 17:26:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++NT+10-Q++++Estrella+Immunopharma%2C++++For%3A+Mar+31/26509663.html si-local-file:///var/storage/secattach/20260518/26509663.html http://www.streetinsider.com/SEC+Filings/Form++NT+10-Q++++Estrella+Immunopharma%2C++++For%3A+Mar+31/26509663.html Mon, 18 May 2026 06:04:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++NT+10-Q++++Estrella+Immunopharma%2C++++For%3A+Mar+31/26509663.html si-local-file:///var/storage/secattach/20260518/26509663.html http://www.streetinsider.com/SEC+Filings/Form++NT+10-Q++++Estrella+Immunopharma%2C++++For%3A+Mar+31/26509663.html Mon, 18 May 2026 06:04:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Estrella+Immunopharma%2C++++For%3A+Mar+31/26509670.html si-local-file:///var/storage/secattach/20260518/26509670.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Estrella+Immunopharma%2C++++For%3A+Mar+31/26509670.html Mon, 18 May 2026 06:04:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Estrella+Immunopharma%2C++++For%3A+Mar+31/26509670.html si-local-file:///var/storage/secattach/20260518/26509670.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Estrella+Immunopharma%2C++++For%3A+Mar+31/26509670.html Mon, 18 May 2026 06:04:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Estrella+Immunopharma%2C+++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26502058.html si-local-file:///var/storage/secattach/20260515/26502058.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Estrella+Immunopharma%2C+++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26502058.html Fri, 15 May 2026 11:16:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Estrella+Immunopharma%2C+++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26502058.html si-local-file:///var/storage/secattach/20260515/26502058.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Estrella+Immunopharma%2C+++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26502058.html Fri, 15 May 2026 11:16:00 -0400 ESLA O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+to+Participate+in+the+D.+Boral+Capital+Global+Conference/26430113.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that its CEO and CFO will participate in one-on-one investor meetings at the D. Boral Capital 2026 Global Conference. </p><p> Hosted by D. Boral Capital, this curated forum at The Plaza Hotel brings together executives from emerging-growth public and private companies to engage directly with institutional investors and strategic partners. </p><p> <b>Date: </b>May 7, 2026 <br /><b>Venue: </b>The Plaza Hotel, New York, NY <br /><b>Website: </b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4673396-1%26h%3D1404733027%26u%3Dhttps%253A%252F%252Fwww.globenewswire.com%252FTracker%253Fdata%253DhVey1IWEOdoWnKr8esNaiTnX4SAPxvUvELUOxTXmnH_7yIvl8Tf4_7uJ6ELQTfKt1XEBPpxCkgKsELVOXQGbArrBhOX-0m-Lit1NHXJS2QIFzqEiS6CMK06oeQMmQwtcZgmiMmzPvmhW1GXhBIdVOjInSU52VOGdZyVBLN-SvZ8%253D%26a%3Dhttps%253A%252F%252Fdboralcapital.com%252Fconference%252F&amp;esheet=54528990&amp;newsitemid=20260505375885&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdboralcapital.com%2Fconference&amp;index=1&amp;md5=56f1aa5cffc4f9f3253ff8543a175340" shape="rect"><b>https://dboralcapital.com/conference</b></a> </p><p> Investors interested http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+to+Participate+in+the+D.+Boral+Capital+Global+Conference/26430113.html Tue, 05 May 2026 08:00:00 -0400 ESLA ESLAW O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+to+Participate+in+the+D.+Boral+Capital+Global+Conference/26430113.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that its CEO and CFO will participate in one-on-one investor meetings at the D. Boral Capital 2026 Global Conference. </p><p> Hosted by D. Boral Capital, this curated forum at The Plaza Hotel brings together executives from emerging-growth public and private companies to engage directly with institutional investors and strategic partners. </p><p> <b>Date: </b>May 7, 2026 <br /><b>Venue: </b>The Plaza Hotel, New York, NY <br /><b>Website: </b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4673396-1%26h%3D1404733027%26u%3Dhttps%253A%252F%252Fwww.globenewswire.com%252FTracker%253Fdata%253DhVey1IWEOdoWnKr8esNaiTnX4SAPxvUvELUOxTXmnH_7yIvl8Tf4_7uJ6ELQTfKt1XEBPpxCkgKsELVOXQGbArrBhOX-0m-Lit1NHXJS2QIFzqEiS6CMK06oeQMmQwtcZgmiMmzPvmhW1GXhBIdVOjInSU52VOGdZyVBLN-SvZ8%253D%26a%3Dhttps%253A%252F%252Fdboralcapital.com%252Fconference%252F&amp;esheet=54528990&amp;newsitemid=20260505375885&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdboralcapital.com%2Fconference&amp;index=1&amp;md5=56f1aa5cffc4f9f3253ff8543a175340" shape="rect"><b>https://dboralcapital.com/conference</b></a> </p><p> Investors interested http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+to+Participate+in+the+D.+Boral+Capital+Global+Conference/26430113.html Tue, 05 May 2026 08:00:00 -0400 ESLA ESLAW O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+to+Participate+in+the+D.+Boral+Capital+Global+Conference/26430113.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that its CEO and CFO will participate in one-on-one investor meetings at the D. Boral Capital 2026 Global Conference. </p><p> Hosted by D. Boral Capital, this curated forum at The Plaza Hotel brings together executives from emerging-growth public and private companies to engage directly with institutional investors and strategic partners. </p><p> <b>Date: </b>May 7, 2026 <br /><b>Venue: </b>The Plaza Hotel, New York, NY <br /><b>Website: </b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4673396-1%26h%3D1404733027%26u%3Dhttps%253A%252F%252Fwww.globenewswire.com%252FTracker%253Fdata%253DhVey1IWEOdoWnKr8esNaiTnX4SAPxvUvELUOxTXmnH_7yIvl8Tf4_7uJ6ELQTfKt1XEBPpxCkgKsELVOXQGbArrBhOX-0m-Lit1NHXJS2QIFzqEiS6CMK06oeQMmQwtcZgmiMmzPvmhW1GXhBIdVOjInSU52VOGdZyVBLN-SvZ8%253D%26a%3Dhttps%253A%252F%252Fdboralcapital.com%252Fconference%252F&amp;esheet=54528990&amp;newsitemid=20260505375885&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdboralcapital.com%2Fconference&amp;index=1&amp;md5=56f1aa5cffc4f9f3253ff8543a175340" shape="rect"><b>https://dboralcapital.com/conference</b></a> </p><p> Investors interested http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+to+Participate+in+the+D.+Boral+Capital+Global+Conference/26430113.html Tue, 05 May 2026 08:00:00 -0400 ESLA ESLAW O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+to+Participate+in+the+D.+Boral+Capital+Global+Conference/26430113.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that its CEO and CFO will participate in one-on-one investor meetings at the D. Boral Capital 2026 Global Conference. </p><p> Hosted by D. Boral Capital, this curated forum at The Plaza Hotel brings together executives from emerging-growth public and private companies to engage directly with institutional investors and strategic partners. </p><p> <b>Date: </b>May 7, 2026 <br /><b>Venue: </b>The Plaza Hotel, New York, NY <br /><b>Website: </b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4673396-1%26h%3D1404733027%26u%3Dhttps%253A%252F%252Fwww.globenewswire.com%252FTracker%253Fdata%253DhVey1IWEOdoWnKr8esNaiTnX4SAPxvUvELUOxTXmnH_7yIvl8Tf4_7uJ6ELQTfKt1XEBPpxCkgKsELVOXQGbArrBhOX-0m-Lit1NHXJS2QIFzqEiS6CMK06oeQMmQwtcZgmiMmzPvmhW1GXhBIdVOjInSU52VOGdZyVBLN-SvZ8%253D%26a%3Dhttps%253A%252F%252Fdboralcapital.com%252Fconference%252F&amp;esheet=54528990&amp;newsitemid=20260505375885&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdboralcapital.com%2Fconference&amp;index=1&amp;md5=56f1aa5cffc4f9f3253ff8543a175340" shape="rect"><b>https://dboralcapital.com/conference</b></a> </p><p> Investors interested http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+to+Participate+in+the+D.+Boral+Capital+Global+Conference/26430113.html Tue, 05 May 2026 08:00:00 -0400 ESLA ESLAW O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+to+Participate+in+the+D.+Boral+Capital+Global+Conference/26430113.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that its CEO and CFO will participate in one-on-one investor meetings at the D. Boral Capital 2026 Global Conference. </p><p> Hosted by D. Boral Capital, this curated forum at The Plaza Hotel brings together executives from emerging-growth public and private companies to engage directly with institutional investors and strategic partners. </p><p> <b>Date: </b>May 7, 2026 <br /><b>Venue: </b>The Plaza Hotel, New York, NY <br /><b>Website: </b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4673396-1%26h%3D1404733027%26u%3Dhttps%253A%252F%252Fwww.globenewswire.com%252FTracker%253Fdata%253DhVey1IWEOdoWnKr8esNaiTnX4SAPxvUvELUOxTXmnH_7yIvl8Tf4_7uJ6ELQTfKt1XEBPpxCkgKsELVOXQGbArrBhOX-0m-Lit1NHXJS2QIFzqEiS6CMK06oeQMmQwtcZgmiMmzPvmhW1GXhBIdVOjInSU52VOGdZyVBLN-SvZ8%253D%26a%3Dhttps%253A%252F%252Fdboralcapital.com%252Fconference%252F&amp;esheet=54528990&amp;newsitemid=20260505375885&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdboralcapital.com%2Fconference&amp;index=1&amp;md5=56f1aa5cffc4f9f3253ff8543a175340" shape="rect"><b>https://dboralcapital.com/conference</b></a> </p><p> Investors interested http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+to+Participate+in+the+D.+Boral+Capital+Global+Conference/26430113.html Tue, 05 May 2026 08:00:00 -0400 ESLA ESLAW O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+to+Participate+in+the+D.+Boral+Capital+Global+Conference/26430113.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that its CEO and CFO will participate in one-on-one investor meetings at the D. Boral Capital 2026 Global Conference. </p><p> Hosted by D. Boral Capital, this curated forum at The Plaza Hotel brings together executives from emerging-growth public and private companies to engage directly with institutional investors and strategic partners. </p><p> <b>Date: </b>May 7, 2026 <br /><b>Venue: </b>The Plaza Hotel, New York, NY <br /><b>Website: </b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4673396-1%26h%3D1404733027%26u%3Dhttps%253A%252F%252Fwww.globenewswire.com%252FTracker%253Fdata%253DhVey1IWEOdoWnKr8esNaiTnX4SAPxvUvELUOxTXmnH_7yIvl8Tf4_7uJ6ELQTfKt1XEBPpxCkgKsELVOXQGbArrBhOX-0m-Lit1NHXJS2QIFzqEiS6CMK06oeQMmQwtcZgmiMmzPvmhW1GXhBIdVOjInSU52VOGdZyVBLN-SvZ8%253D%26a%3Dhttps%253A%252F%252Fdboralcapital.com%252Fconference%252F&amp;esheet=54528990&amp;newsitemid=20260505375885&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdboralcapital.com%2Fconference&amp;index=1&amp;md5=56f1aa5cffc4f9f3253ff8543a175340" shape="rect"><b>https://dboralcapital.com/conference</b></a> </p><p> Investors interested http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+to+Participate+in+the+D.+Boral+Capital+Global+Conference/26430113.html Tue, 05 May 2026 08:00:00 -0400 ESLA ESLAW O.52433315 http://www.streetinsider.com/SEC+Filings/Form++10-KA+++++Estrella+Immunopharma%2C++++For%3A+Dec+31/26410358.html si-local-file:///var/storage/secattach/20260430/26410358.html http://www.streetinsider.com/SEC+Filings/Form++10-KA+++++Estrella+Immunopharma%2C++++For%3A+Dec+31/26410358.html Thu, 30 Apr 2026 17:28:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++10-KA+++++Estrella+Immunopharma%2C++++For%3A+Dec+31/26410358.html si-local-file:///var/storage/secattach/20260430/26410358.html http://www.streetinsider.com/SEC+Filings/Form++10-KA+++++Estrella+Immunopharma%2C++++For%3A+Dec+31/26410358.html Thu, 30 Apr 2026 17:28:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Estrella+Immunopharma%2C++++For%3A+Sep+11++Filed+by%3A+Xu+Jiandong/26397835.html si-local-file:///var/storage/secattach/20260429/26397835.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Estrella+Immunopharma%2C++++For%3A+Sep+11++Filed+by%3A+Xu+Jiandong/26397835.html Wed, 29 Apr 2026 21:37:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Estrella+Immunopharma%2C++++For%3A+Sep+11++Filed+by%3A+Xu+Jiandong/26397835.html si-local-file:///var/storage/secattach/20260429/26397835.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Estrella+Immunopharma%2C++++For%3A+Sep+11++Filed+by%3A+Xu+Jiandong/26397835.html Wed, 29 Apr 2026 21:37:00 -0400 ESLA O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma%2C+Inc.+%28NASDAQ%3A+ESLA%29+Receives+Initiating+Coverage+with+a+Valuation+of+%2412.00Share+from+Zacks+Small-Cap+Research/26200724.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that Zacks Small-Cap Research (“Zacks SCR”), a division of Zacks Investment Research, has initiated coverage on the Company, assigning a valuation of $12.00 per share. The coverage report highlights the Company’s differentiated ARTEMIS platform and encouraging early clinical data from the Phase I/II STARLIGHT-1 trial of EB103. </p><p> “The recent $7.8 billion acquisition of Arcellx by Gilead Sciences underscores the premium that large biopharmaceutical companies continue to http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma%2C+Inc.+%28NASDAQ%3A+ESLA%29+Receives+Initiating+Coverage+with+a+Valuation+of+%2412.00Share+from+Zacks+Small-Cap+Research/26200724.html Mon, 23 Mar 2026 08:00:00 -0400 A.05758741 A.50214643 ESLA ESLAW O.22209695 O.35847762 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma%2C+Inc.+%28NASDAQ%3A+ESLA%29+Receives+Initiating+Coverage+with+a+Valuation+of+%2412.00Share+from+Zacks+Small-Cap+Research/26200724.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that Zacks Small-Cap Research (“Zacks SCR”), a division of Zacks Investment Research, has initiated coverage on the Company, assigning a valuation of $12.00 per share. The coverage report highlights the Company’s differentiated ARTEMIS platform and encouraging early clinical data from the Phase I/II STARLIGHT-1 trial of EB103. </p><p> “The recent $7.8 billion acquisition of Arcellx by Gilead Sciences underscores the premium that large biopharmaceutical companies continue to http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma%2C+Inc.+%28NASDAQ%3A+ESLA%29+Receives+Initiating+Coverage+with+a+Valuation+of+%2412.00Share+from+Zacks+Small-Cap+Research/26200724.html Mon, 23 Mar 2026 08:00:00 -0400 A.05758741 A.50214643 ESLA ESLAW O.22209695 O.35847762 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma%2C+Inc.+%28NASDAQ%3A+ESLA%29+Receives+Initiating+Coverage+with+a+Valuation+of+%2412.00Share+from+Zacks+Small-Cap+Research/26200724.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that Zacks Small-Cap Research (“Zacks SCR”), a division of Zacks Investment Research, has initiated coverage on the Company, assigning a valuation of $12.00 per share. The coverage report highlights the Company’s differentiated ARTEMIS platform and encouraging early clinical data from the Phase I/II STARLIGHT-1 trial of EB103. </p><p> “The recent $7.8 billion acquisition of Arcellx by Gilead Sciences underscores the premium that large biopharmaceutical companies continue to http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma%2C+Inc.+%28NASDAQ%3A+ESLA%29+Receives+Initiating+Coverage+with+a+Valuation+of+%2412.00Share+from+Zacks+Small-Cap+Research/26200724.html Mon, 23 Mar 2026 08:00:00 -0400 A.05758741 A.50214643 ESLA ESLAW O.22209695 O.35847762 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma%2C+Inc.+%28NASDAQ%3A+ESLA%29+Receives+Initiating+Coverage+with+a+Valuation+of+%2412.00Share+from+Zacks+Small-Cap+Research/26200724.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that Zacks Small-Cap Research (“Zacks SCR”), a division of Zacks Investment Research, has initiated coverage on the Company, assigning a valuation of $12.00 per share. The coverage report highlights the Company’s differentiated ARTEMIS platform and encouraging early clinical data from the Phase I/II STARLIGHT-1 trial of EB103. </p><p> “The recent $7.8 billion acquisition of Arcellx by Gilead Sciences underscores the premium that large biopharmaceutical companies continue to http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma%2C+Inc.+%28NASDAQ%3A+ESLA%29+Receives+Initiating+Coverage+with+a+Valuation+of+%2412.00Share+from+Zacks+Small-Cap+Research/26200724.html Mon, 23 Mar 2026 08:00:00 -0400 A.05758741 A.50214643 ESLA ESLAW O.22209695 O.35847762 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma%2C+Inc.+%28NASDAQ%3A+ESLA%29+Receives+Initiating+Coverage+with+a+Valuation+of+%2412.00Share+from+Zacks+Small-Cap+Research/26200724.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that Zacks Small-Cap Research (“Zacks SCR”), a division of Zacks Investment Research, has initiated coverage on the Company, assigning a valuation of $12.00 per share. The coverage report highlights the Company’s differentiated ARTEMIS platform and encouraging early clinical data from the Phase I/II STARLIGHT-1 trial of EB103. </p><p> “The recent $7.8 billion acquisition of Arcellx by Gilead Sciences underscores the premium that large biopharmaceutical companies continue to http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma%2C+Inc.+%28NASDAQ%3A+ESLA%29+Receives+Initiating+Coverage+with+a+Valuation+of+%2412.00Share+from+Zacks+Small-Cap+Research/26200724.html Mon, 23 Mar 2026 08:00:00 -0400 A.05758741 A.50214643 ESLA ESLAW O.22209695 O.35847762 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma%2C+Inc.+%28NASDAQ%3A+ESLA%29+Receives+Initiating+Coverage+with+a+Valuation+of+%2412.00Share+from+Zacks+Small-Cap+Research/26200724.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that Zacks Small-Cap Research (“Zacks SCR”), a division of Zacks Investment Research, has initiated coverage on the Company, assigning a valuation of $12.00 per share. The coverage report highlights the Company’s differentiated ARTEMIS platform and encouraging early clinical data from the Phase I/II STARLIGHT-1 trial of EB103. </p><p> “The recent $7.8 billion acquisition of Arcellx by Gilead Sciences underscores the premium that large biopharmaceutical companies continue to http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma%2C+Inc.+%28NASDAQ%3A+ESLA%29+Receives+Initiating+Coverage+with+a+Valuation+of+%2412.00Share+from+Zacks+Small-Cap+Research/26200724.html Mon, 23 Mar 2026 08:00:00 -0400 A.05758741 A.50214643 ESLA ESLAW O.22209695 O.35847762 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma%2C+Inc.+%28NASDAQ%3A+ESLA%29+Receives+Initiating+Coverage+with+a+Valuation+of+%2412.00Share+from+Zacks+Small-Cap+Research/26200724.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that Zacks Small-Cap Research (“Zacks SCR”), a division of Zacks Investment Research, has initiated coverage on the Company, assigning a valuation of $12.00 per share. The coverage report highlights the Company’s differentiated ARTEMIS platform and encouraging early clinical data from the Phase I/II STARLIGHT-1 trial of EB103. </p><p> “The recent $7.8 billion acquisition of Arcellx by Gilead Sciences underscores the premium that large biopharmaceutical companies continue to http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma%2C+Inc.+%28NASDAQ%3A+ESLA%29+Receives+Initiating+Coverage+with+a+Valuation+of+%2412.00Share+from+Zacks+Small-Cap+Research/26200724.html Mon, 23 Mar 2026 08:00:00 -0400 A.05758741 A.50214643 ESLA ESLAW O.22209695 O.35847762 O.52433315